Publish in this journal
Journal Information
Vol. 69. Issue 5.
Pages 533 (May 2016)
Share
Share
Download PDF
More article options
Vol. 69. Issue 5.
Pages 533 (May 2016)
Letter to the Editor
DOI: 10.1016/j.rec.2016.01.023
Full text access
Evidence From Pacing in Obstructive Hypertrophic Cardiomyopathy. Response
Evidencia del tratamiento con marcapasos en la miocardiopatía hipertrófica obstructiva. Respuesta
Visits
...
Alfonso Jurado Román, José M. Montero Cabezas
Corresponding author
jmmonterocabezas@gmail.com

Corresponding author:
, Juan C. Tascón Pérez
Departamento de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain
Related content
Rev Esp Cardiol. 2016;69:53210.1016/j.rec.2016.01.014
Miriam Sandín, Vicente Climent, Gonzalo de la Morena, Francisco Marín
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
To the Editor,

We thank the authors for their comments and share their opinion on the limited role of atrioventricular sequential pacing (AVSP) in clinical practice guidelines, given that these recommendations are primarily based on 3 small placebo-controlled trials that are not without limitations.1 The superiority of septal reduction techniques over AVSP has also only been shown in highly specialized centers. The shortage of such centers in Spain and the undesirably high morbidity and mortality associated with septal reduction techniques (15% in myectomy and 40% in septal ablation) make AVSP an appealing strategy in suitably selected patients.

In addition, AVSP has shown greater clinical benefit in elderly patients with more pronounced baseline functional impairment.1 Thus, the notable improvement in the subjective functional class described in our study could be related to the high average age of the patients in our sample (66 years) and the high percentage of them in an advanced functional class (93% in New York Heart Association [NYHA] class III-IV). Although the average patient age in the study by Sandín et al2 was similar to that of our cohort, their study did not include patients in functional class IV and only 62.9% were in class III, possibly explaining the differences in functional improvement. Despite the large sample size and long-term follow-up, we recognize that one of the main limitations of our study is the absence of an objective evaluation of the functional class. Although subjective evaluation of the functional class via the NYHA classification continues to play a large role in determining changes in clinical practice, it would undoubtedly be usefulto design studies objectively analyzing the effects of AVSP through not only conventionalexercise testing (requiring indirect inference of the functional class), but also oxygen consumption studies.

References
[1]
A. Jurado Román, J.M. Montero Cabezas, B. Rubio Alonso, J. García Tejada, F. Hernández Hernández, A. Albarrán González-Trevilla, et al.
Estimulación auriculoventricular secuencial en pacientes con miocardiopatía hipertrófica: 18 años de experiencia.
Rev Esp Cardiol., 69 (2016), pp. 377-383
[2]
M. Sandín, F. Marín, F. Cambronero, V. Climent, C. Caro, J.G. Martínez, et al.
¿Existe un efecto beneficioso a largo plazo con el tratamiento con marcapasos de la miocardiopatía hipertrófica obstructiva severa?.
Rev Esp Cardiol., 62 (2009), pp. 1233-1239
Copyright © 2016. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?